• Epizyme Inc., of Cambridge, Mass., said it initiated a Phase I study of EPZ-5676, a small-molecule inhibitor of histone methyltransferase DOT1L, to evaluate the drug's safety, pharmacokinetics and pharmacodynamics in escalating doses.